Expanding ALS Trial Eligibility Could Benefit Patients, Therapeutic Progress

Expanding eligibility criteria for early-phase ALS clinical trials could benefit both patients and therapeutic progress, according to experts. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which has ethical and drug development implications. Angela Genge, chief medical officer at QurAlis, believes that expanding eligibility is necessary to allow..